Morgan Stanley analyst Jack Lin initiated coverage of Zai Lab with an Overweight rating and $47.50 price target. Zai Lab, a “biotech leader” in China’s in-licensing strategy space, should benefit as in-licensing names re-rate under favorable tailwinds with 40% of its pipeline having “first-in-class potential,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZLAB:
- Zai Lab price target lowered to $123 from $128 at Citi
- Zai Lab reports Q3 EPS (71c), consensus (95c)
- Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
- Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Zai Lab price target lowered to $64 from $67 at JPMorgan
